Mesoblast (ASX:MSB) Stock Based Compensation : A$1.65 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Mesoblast Stock Based Compensation?

Mesoblast's Stock Based Compensation for the three months ended in Dec. 2023 was A$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was A$1.65 Mil.

Mesoblast Stock Based Compensation Historical Data

The historical data trend for Mesoblast's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Stock Based Compensation Chart

Mesoblast Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Stock Based Compensation

Get a 7-Day Free Trial

6.29

10.90

16.36

7.88

5.45

Mesoblast Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Stock Based Compensation	Get a 7-Day Free Trial															1.18	1.65	-	-	-

Mesoblast Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was A$1.65 Mil.

Mesoblast Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Mesoblast's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (ASX:MSB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany

Address

Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.